ARID1A is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ARID1A status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

ATM is an inclusion eligibility criterion in 21 clinical trials for prostate adenocarcinoma, of which 18 are open and 3 are closed. Of the trials that contain ATM status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 18 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].

ATR is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 15 are open and 2 are closed. Of the trials that contain ATR status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (12 open), and 2 are phase 3 (2 open) [3].

ATRX is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ATRX status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 15 are open and 2 are closed. Of the trials that contain BARD1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (12 open), and 2 are phase 3 (2 open) [3].

BRCA1 is an inclusion eligibility criterion in 20 clinical trials for prostate adenocarcinoma, of which 17 are open and 3 are closed. Of the trials that contain BRCA1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].

BRCA2 is an inclusion eligibility criterion in 20 clinical trials for prostate adenocarcinoma, of which 17 are open and 3 are closed. Of the trials that contain BRCA2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].

BRIP1 is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain BRIP1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

C11orf30 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain C11orf30 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 21 clinical trials for prostate adenocarcinoma, of which 18 are open and 3 are closed. Of the trials that contain CDK12 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 18 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].

CHEK1 is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 15 are open and 2 are closed. Of the trials that contain CHEK1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (12 open), and 2 are phase 3 (2 open) [3].

CHEK2 is an inclusion eligibility criterion in 20 clinical trials for prostate adenocarcinoma, of which 18 are open and 2 are closed. Of the trials that contain CHEK2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC2 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERCC2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

ERCC3 is an inclusion eligibility criterion in 10 clinical trials for prostate adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain ERCC3 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].

ERCC4 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERCC4 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

ERCC5 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERCC5 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

ERCC6 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERCC6 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

FAM175A is an inclusion eligibility criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FAM175A status and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is an inclusion eligibility criterion in 20 clinical trials for prostate adenocarcinoma, of which 17 are open and 3 are closed. Of the trials that contain FANCA status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].

FANCB is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain FANCB status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

FANCC is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain FANCC status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

FANCD2 is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain FANCD2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

FANCE is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain FANCE status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

FANCF is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain FANCF status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

FANCG is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain FANCG status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

FANCI is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain FANCI status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

FANCL is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain FANCL status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

FANCM is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain FANCM status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

GEN1 is an inclusion eligibility criterion in 2 clinical trials for prostate adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain GEN1 status and prostate adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

HDAC1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain HDAC1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain HDAC2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 8 clinical trials for prostate adenocarcinoma, of which 7 are open and 1 is closed. Of the trials that contain MCPH1 status and prostate adenocarcinoma as inclusion criteria, 7 are phase 2 (6 open) and 1 is phase 3 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain MDM2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain MDM4 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain MLF1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 12 clinical trials for prostate adenocarcinoma, of which 11 are open and 1 is closed. Of the trials that contain MLH1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 10 are phase 2 (9 open), and 1 is phase 3 (1 open) [3].

MLH3 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain MLH3 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain MRE11A status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

MSH2 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain MSH2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].

MSH3 is an inclusion eligibility criterion in 10 clinical trials for prostate adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain MSH3 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain MSH6 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].

MUTYH is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain MUTYH status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

NBN is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain NBN status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

NPM1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain NPM1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 20 clinical trials for prostate adenocarcinoma, of which 17 are open and 3 are closed. Of the trials that contain PALB2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].

PARP1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain PARP1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain PARP2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

PMS1 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain PMS1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain PMS2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].

POLE is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain POLE status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

PPP2R1A is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain PPP2R1A status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 10 clinical trials for prostate adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain PPP2R2A status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].

PTEN is an inclusion eligibility criterion in 10 clinical trials for prostate adenocarcinoma, of which 8 are open and 2 are closed. Of the trials that contain PTEN status and prostate adenocarcinoma as inclusion criteria, 9 are phase 2 (7 open) and 1 is phase 3 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain RAD50 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

RAD51 is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 15 are open and 2 are closed. Of the trials that contain RAD51 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (12 open), and 2 are phase 3 (2 open) [3].

RAD51B is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 15 are open and 2 are closed. Of the trials that contain RAD51B status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (12 open), and 2 are phase 3 (2 open) [3].

RAD51C is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain RAD51C status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

RAD51D is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain RAD51D status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].

RAD54L is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 15 are open and 2 are closed. Of the trials that contain RAD54L status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (12 open), and 2 are phase 3 (2 open) [3].

RB1 is an inclusion eligibility criterion in 2 clinical trials for prostate adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RB1 status and prostate adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

SLX4 is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 15 are open and 2 are closed. Of the trials that contain SLX4 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (12 open), and 2 are phase 3 (2 open) [3].

SMARCB1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain SMARCB1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain STAG2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

STK11 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain STK11 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain XRCC1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].